Analysis of proteoglycan synthesis by retro-ocular tissue fibroblasts under the influence of interleukin 1 beta and transforming growth factor-beta.
Retro-ocular tissue fibroblasts are supposed to be responsible for the deposition of glycosaminoglycan in Graves' ophthalmopathy. We have reported in a preliminary fashion that interleukin 1 beta (IL-1 beta) and transforming growth factor-beta (TGF-beta) increased the rate of [35S]sulfate incorporation into proteoglycans two to five times the control in culture of retro-ocular tissue fibroblasts. The increase in the rate of [35S]sulfate incorporation into proteoglycan will occur as a result of: (a) net increase of proteoglycan synthesis; (b) elongation of glycosaminoglycan chains; (c) increased number of glycosaminoglycan chains; (d) oversulfation of glycosaminoglycan chains; (e) increase in cell number; (f) decreased rate of degradation. We have analyzed which mechanism is important for the increase of [35S]sulfate into proteoglycans observed in human retro-ocular tissue fibroblasts under the influence of cytokines. The last two possibilities (e, f) were ruled out because during the observation period there was no consistent proliferation of the cells and no decrease in the rate of degradation of proteoglycan examined by pulse-chase experiment. Cytokines did not change the size of glycosaminoglycan chains released from proteoglycan as measured by alkaline borohydride treatment, ruling out (b). Disaccharide analysis by HPLC after chondroitin sulfate ABC digestion revealed that glycosaminoglycan mainly contains monosulfated chondroitin disaccharides and that oversulfation was not observed under the influence of IL-1 beta or TGF-beta, ruling out (d). The capacity to synthesize glycosaminoglycan chain in the presence of an artifical acceptor of chain elongation, beta-D-xylodide, was increased significantly by IL-1 beta but not obviously so by TGF-beta.(ABSTRACT TRUNCATED AT 250 WORDS)
Imai
Y
Y
Bone Research Branch, National Institute of Dental Research, National Institutes of Health, Bethesda, MD.
Ibaraki
K
K
Odajima
R
R
Shishiba
Y
Y
D003238:Connective Tissue / Q000378:metabolism*; D003239:Connective Tissue Cells; D016207:Cytokines / Q000494:pharmacology; D005347:Fibroblasts / Q000378:metabolism; D006025:Glycosaminoglycans / Q000096:biosynthesis / Q000737:chemistry; D006027:Glycosides / Q000494:pharmacology; D006111:Graves Disease / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology*; D009915:Orbit / Q000166:cytology / Q000378:metabolism*; D011509:Proteoglycans / Q000096:biosynthesis* / Q000235:genetics; D012333:RNA, Messenger / Q000378:metabolism; D012867:Skin / Q000166:cytology / Q000378:metabolism; D013431:Sulfates / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
D016207:Cytokines; D006025:Glycosaminoglycans; D006027:Glycosides; D007375:Interleukin-1; D011509:Proteoglycans; D012333:RNA, Messenger; D013431:Sulfates; D016212:Transforming Growth Factor beta; C010807:xylosides